Influenza A virus H9N2 vaccine - Ology Bioservices

Drug Profile

Influenza A virus H9N2 vaccine - Ology Bioservices

Alternative Names: H9N2 vaccine - Ology Bioservices; Reverse genetic reassortant H9N2 influenza vaccine

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator
  • Developer Ology Bioservices
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza A virus H9N2 subtype

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 25 Oct 2016 Phase-II clinical trials in Influenza-A virus H9N2 subtype in USA (IM)
  • 30 Sep 2015 No recent reports on development identified - Phase-I/II for Influenza-A virus H9N2 subtype (In volunteers) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top